VX-661

DRUG3 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 1

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

CompletedNCT02015507

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2014-01-31End: 2014-02-28Updated: 2014-03-26

Phase 2

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

CompletedNCT01531673

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2012-02-29End: 2014-03-31Updated: 2018-04-13

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

CompletedNCT02070744

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2014-03-31End: 2016-05-27Updated: 2025-09-24

Related Papers

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and <i>F508del</i> / <i>F508del-CFTR</i> or <i>F508del</i> / <i>G551D-CFTR</i>

American Journal of Respiratory and Critical Care Medicine2017-09-20174 citations